Document Detail

Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome.
MedLine Citation:
PMID:  21735428     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Laryngeal mask airway (LMA) administration is one way of delivering surfactant to the infant lung, with the potential benefit of avoiding endotracheal intubation and ventilation, ventilator induced lung injury and bronchopulmonary dysplasia (BPD).
OBJECTIVES: To determine the effect of LMA surfactant administration either as prophylaxis or treatment compared to placebo, no treatment, or intratracheal surfactant administration on morbidity and mortality in preterm infants with, or at risk of, respiratory distress syndrome (RDS).
SEARCH STRATEGY: We searched CENTRAL (The Cochrane Library, October 2010), MEDLINE and PREMEDLINE (1950 to October 2010), EMBASE (1980 to October 2010) and CINAHL (1982 to October 2010). We also searched proceedings of scientific meetings, clinical trial registries, Google Scholar and reference lists of identified studies, as well as contacting expert informants and surfactant manufacturers.
SELECTION CRITERIA: Randomised, cluster-randomised or quasi-randomised controlled trials of laryngeal mask surfactant administration compared to placebo, no treatment, or other routes of administration (nebulised, pharyngeal instillation of surfactant before the first breath, thin endotracheal catheter surfactant administration or intratracheal surfactant instillation) on morbidity and mortality in preterm infants at risk of RDS. We considered published, unpublished and ongoing trials.
DATA COLLECTION AND ANALYSIS: Two review authors independently assessed studies for eligibility and quality, and extracted data.
MAIN RESULTS: We found no studies of prophylactic or early LMA surfactant administration. A single small study of late rescue LMA surfactant was identified as eligible for inclusion. The study enrolled 26 preterm infants born ≥ 1200 g with RDS on continuous positive airway pressure (nCPAP). LMA surfactant administration compared to no treatment resulted in a reduction in mean FiO(2) required to maintain oxygen saturation between 88% and 92% for 12 hours after the intervention. No significant difference was reported in subsequent mechanical ventilation and endotracheal surfactant, pneumothorax, days on intermittent positive airway pressure (IPPV), and days on IPPV or oxygen.
AUTHORS' CONCLUSIONS: There is evidence from a single small trial that LMA surfactant administration in preterm infants ≥ 1200 g with established RDS may have a short term effect in reducing oxygen requirements although the study is underpowered to detect important clinical effects. Adequately powered trials are required to determine the effect of LMA surfactant administration for prevention or treatment of RDS in preterm infants. LMA surfactant administration should be limited to clinical trials.
Mohamed E Abdel-Latif; David A Osborn
Related Documents :
17550598 - Azithromycin in the extremely low birth weight infant for the prevention of bronchopulm...
20297898 - Outcomes of extremely low birth weight infants with varying doses and intervals of ante...
14730268 - Predisposition of infants with chronic lung disease to respiratory syncytial virus-indu...
21735428 - Laryngeal mask airway surfactant administration for prevention of morbidity and mortali...
15305108 - Conversion to dementia among two groups with cognitive impairment. a preliminary report.
2698148 - Development of the thyroid.
Publication Detail:
Type:  Journal Article; Review     Date:  2011-07-06
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  -     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2011  
Date Detail:
Created Date:  2011-07-07     Completed Date:  2011-08-02     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  CD008309     Citation Subset:  IM    
Department of Neonatology, Australian National University Medical School, PO Box 11, Woden, ACT, Australia, 2606.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bronchopulmonary Dysplasia / prevention & control
Continuous Positive Airway Pressure*
Infant, Newborn
Infant, Premature
Laryngeal Masks*
Pulmonary Surfactants / administration & dosage*
Randomized Controlled Trials as Topic
Respiratory Distress Syndrome, Newborn / drug therapy*,  mortality
Reg. No./Substance:
0/Pulmonary Surfactants

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chinese herbal medicines for hypercholesterolemia.
Next Document:  Interventions to manage dual practice among health workers.